GLP‑1s and Eating Disorders: A CBT‑E Therapist’s Perspective on the “Easy Fix”

Written by Melissa Harrison, LPC

After more than 15 years of treating eating disorders, including binge eating disorder, I’ve spent thousands of hours working with people maneuvering the painful overlap of eating, body image, and shame. As I’ve thought about GLP-1 medication in the eating disorder space, I’ve come to see GLP-1 medications as a kind of mirror for our culture. They reflect the promise of modern medicine and the deep, unresolved pathologies of weight stigma and diet culture. In this blog, I will walk through what GLP‑1s are, who is using them, what the emerging literature suggests (and warns against), and why the eating‑disorder and CBT‑E community must reckon with them.

What Are GLP‑1s and Why Are So Many People Using Them?
GLP‑1 receptor agonists (like Ozempic and Wegovy) are medications originally developed and approved for type 2 diabetes. They work by:

Stimulating insulin release,
Suppressing glucagon,
Slowing gastric emptying, and
Acting on brain pathways that regulate appetite and satiety.

In practice, this means people feel fuller sooner, eat less, and often lose weight, and sometimes a lot, and quickly. Not surprisingly, these drugs have been adopted for weight‑loss purposes in high numbers, especially in the last couple of years. And, they have been used for people with eating disorders, despite not b eing approved for eating‑disorder treatment.

Current data suggest that GLP‑1RAs are now among the most‑prescribed medications in the world for weight management, with over 120 similar drugs in development. They are not just prescribed for people with diabetes, but increasingly for people classified as “overweight” or “obese.” Now, the way we talk about weight in medicine is incredibly complicated. The medical community often describes obesity as a disease and points to its association with conditions like cardiovascular disease, diabetes, and kidney disease. It’s important is note, however, that while those conditions may often be associated with higher weight, hat does not always mean that body size itself is the variable actually causing them. Some associations may be causal, some may be partly explained by other factors, and some may be bidirectional or influenced by things like stigma, access to care, nutrition, stress, movement, sleep, genetics, poverty, and medical history. In other words, a higher BMI should not automatically be treated as proof that weight itself is the sole underlying problem.

This distinction is especially important when we look at research like the study by Matheson, King, and Everett (2012), which found that healthy behaviors significantly reduced mortality risk across all BMI categories. Their findings suggest that daily habits, such as movement, nutrition, smoking status, and alcohol use, may tell us more about a person’s health risk than BMI. Why talk about this now? Because many people are being encouraged by providers to start GLP-1 medications primarily to lose weight. For some people, these medications may be helpful and even life-changing. But weight loss alone should not be treated as the whole intervention, and many of these drugs are not necessarily providing risk information or nutritional counseling, and a great emphasis on weight loss and management alone is stressed.

Further highlighting the microcosm of our culture, sometimes even to those who are within a “normal” weight range but desire further thinness will begin using a GLP1. This surge is driven by a cultural hunger for an “easy fix” to weight: a desire magnified by decades of antifat bias, media glorification of thinness, and systemic discrimination against people in larger bodies.

Why the Eating‑Disorder Community Can’t Look Away
This is such a complex conversation with layers of nuance to consider. That said, the eating‑disorder field is uniquely positioned to see how quickly a medical advance can become a psychological trap. GLP‑1RAs are not just supporting blood sugar; they are shaping identities, self‑worth, and behavior. For people with binge‑eating disorder (BED), bulimia, or a history of anorexia, the question is not just, “Do these drugs make it easier to lose weight?” but, “What do they help us avoid? And why do I want to be smaller?”

Many of my BED clients tell me they want to stop bingeing because shame and disgust are unbearable. They want relief. When they hear that GLP‑1s can reduce hunger, suppress urges, and shrink their bodies, it sounds like salvation. From a clinical perspective, I see an urgent need for our field to move beyond “for” or “against” debates and into preparation. We must be ready to talk about these drugs with empathy, curiosity, and a clear, evidence‑informed stance.

What Does the Literature Actually Say?
So, what DOES the evidence and research say? The current research on GLP‑1RAs and eating disorders is still emerging, small, and relatively short‑term, but it suggests a complicated picture. Pilot data and small trials suggest that GLP‑1RAs may reduce binge‑eating episodes and cravings in some individuals with BED or BN, likely by dampening food‑reward pathways and enhancing satiety signaling. Some protocols are explicitly examining GLP‑1RAs as adjuncts to cognitive‑behavioral therapy for eating disorders (CBT‑E), including a study in Norway that combines GLP‑1 medication with CBT‑E to specifically target binge urges. This trial is not focused on “curing” binge eating with a pill, but on testing whether pharmacologic appetite suppression can reduce the intensity of binge urges while evidence‑based therapy works on the underlying mechanisms.

However, the cautionary notes are significant. GLP‑1RAs are not approved for treating any eating disorder. Any use in this population is currently off‑label. The available evidence is limited in duration, sample size, and generalizability. Long‑term effects on binge‑eating trajectories, relapse, and body‑image relationships are largely unknown. Studies on weight loss with GLP‑1RAs show impressive short‑term results, but weight often plateaus and rebounds after discontinuation. This pattern alone raises concerns about what will happen when appetite suppression wanes and the underlying psychological drivers of bingeing remain unaddressed.

There is also emerging concern that GLP‑1‑induced appetite suppression can intensify or mimic restrictive eating patterns, potentially feeding a medication‑type “anorexia” or maintaining rigid control over food intake. It is also confusing how using a GLP-1 while entering in CBT-E treatment would not be counterindicated. There is growing concern that the appetite suppression caused by GLP-1 medications can sometimes resemble, intensify, or reinforce restrictive eating patterns. For clients with eating disorders, this raises important clinical questions. For example, it can be difficult to understand how a person could be actively using a medication that suppresses appetite and often leads to weight loss while also entering CBT-E, a treatment that works to reduce the overvaluation of weight, shape, and control over eating. CBT-E often helps clients shift away from organizing their lives around their bodies and food rules. In contrast, GLP-1 treatment can easily increase attention to appetite, weight, body size, and eating behavior.

In other words: the literature suggests GLP‑1s might help some people reduce bingeing in the short term, but it does not yet tell us whether this translates into sustainable recovery or reduced risk of relapse. It also does not tell us how these drugs reshape the internal experience of hunger, body image, and self‑worth.

CBT‑E, Body Image, and the “Weight Loss” Paradox
For those of us grounded in CBT‑E, the core formulation is familiar: individuals with eating disorders over-evaluate their weight and shape, and this over-evaluation becomes the primary driver of their behaviors and emotions. Restriction, bingeing, purging, exercise rituals are all attempts to manage or “fix” a body that feels intolerable.

In BED specifically, the model emphasizes that bingeing is often a physiological and psychological response to cycles of restriction, emotional deprivation, and rigid dieting. When people deprive themselves, they are more likely to binge. When they binge, they feel out of control. When they feel out of control, they choose even more restriction. The cycle continues. This is why using GLP‑1s for weight loss in BED, especially when prescribed explicitly to make someone “smaller,” is conceptually at odds with the CBT‑E formulation. By pharmacologically suppressing appetite, we may be inadvertently reinforcing the very mechanism of restriction that the model identifies as central to the disorder. Some have argued that appetite suppression might “remove” restriction as a trigger for bingeing, but in practice, this often looks less like relief and more like a new, medication‑enabled form of control.

Even if a GLP‑1 temporarily reduces binge urges, it doesn’t address:

Overvaluation of weight and shape,
Negative body image,
Perfectionistic standards,
Difficulties with emotion regulation, or
Interpersonal stressors
Using food as an emotional regulator

And that’s where CBT‑E and DBT‑informed work remain essential. These therapies help people:

Rebuild regular, structured eating patterns,
Reconnect with hunger and fullness cues,
Tolerate uncomfortable emotions without turning to food or restriction,
Challenge black‑and‑white thinking about “good” and “bad” foods, and
Build a self‑concept that is not contingent on body size.

No GLP‑1 can do that.

Body Image, Systemic Pressures, and “Addictive” Weight Loss
Although body image is not formally coded in the DSM for BED, it is a common cognition and a lived reality for most of my patients. For people in larger bodies, body image is often forged in the crucible of fat phobia, systemic discrimination, and relentless social comparison. They have been told their bodies are unhealthy, unlovable, unprofessional, and undesirable for most of their lives. Their bodies are constantly surveilled, commented on, and “managed” by others. In this context, weight loss can feel less like a medical intervention and more like the psychological relief they’ve been seeking. For someone who has been taught that their worth is tied to their size, rapid, visible change can be intoxicating. This is the “addictive” quality of weight‑loss culture: it offers a temporary antidote to a chronic, body‑shamed identity and lots of praise from others.

When GLP‑1s enter this landscape, they can become a tool for pursuing thinness under the guise of “health.” For people who are already vulnerable to rigid control, perfectionism, and black‑and‑white thinking, these drugs can easily feed an anorexic mindset, either by intensifying restriction, maintaining a preoccupation with “how small can I get,” or normalizing the idea that one’s body is unacceptable without medical intervention.

This is not hypothetical. Eating‑disorder clinicians are already reporting seeing adolescents and adults who begin GLP‑1s for weight loss and then slide into entrenched restriction, excessive exercise, and persistent body dissatisfaction. The drugs are not causing these phenotypes out of thin air; they are amplifying existing vulnerabilities.

Why We Need Informed Consent and Psychological Screening
If we agree that GLP‑1s can be powerfully psychologically potent, then it follows that their use should require at least as much psychological scrutiny as other high‑risk interventions.

Patients prescribed opioids receive detailed information about dependence, addiction, and misuse. Those undergoing bariatric surgery are routinely required to undergo psychological evaluation and counseling before surgery, because we know that weight‑loss procedures alone do not resolve eating‑disorder psychopathology. Why, then, are we so casual about GLP‑1RAs?

The medications are not benign. They come with:

Significant gastrointestinal side effects,
Concerns about long‑term metabolic and cardiovascular safety,
Potential to disrupt regular eating patterns and nutritional rehabilitation,
And the very real risk of misuse in vulnerable populations, including those with or at risk for eating disorders.

For someone who is already engaging in dietary restriction, bingeing, or body‑shame cycles, adding a potent appetite suppressant can tip a fragile system into a full‑blown eating‑disorder trajectory. This is not a minor risk; it is a foreseeable one.

A Call to Action: Physicians, Patients, and Therapists
So what do we do? Below, I share some suggestions based on the research.

For physicians:
Continue to prescribe GLP‑1s when medically indicated, but insist on concurrent psychological screening and monitoring for eating‑disorder risk, especially in patients who are overweight, obese, or have a history of dieting or body‑image distress.
Make clear that GLP‑1s are not a treatment for eating disorders. For BED, emphasize that evidence‑based psychotherapy (CBT‑E, DBT‑informed work, and other gold‑standards) should be recommended alongside or even instead of GLP‑1s.
Provide patients with informed‑consent documents that explicitly outline the risks of medication‑induced restriction, rebound bingeing, and the potential for exacerbating or triggering eating‑disorder symptoms.
For pharma and regulatory bodies:
Include clear warnings about eating‑disorder risk in prescribing information and patient‑facing materials.
Fund and support longitudinal research on how GLP‑1s affect binge‑eating trajectories, body‑image disturbance, and relapse rates in patients with or at risk for EDs.
For therapists (especially CBT‑E providers):
Be prepared to talk about GLP‑1s without judgment. Understand why a client might want one, and sit with the complexity of their desire for relief and thinness.
When appropriate, collaborate with medical providers to consider whether discontinuation or dose adjustment is safer for long‑term recovery.
Use the conversation as an opportunity to educate:
- Explain that GLP‑1s may temporarily reduce binge urges but do not touch the core mechanisms of BED (overvaluation of weight and shape, emotion dysregtogrouped, perfectionism).
- Highlight that appetite suppression can reinforce restriction and create a medication‑type anorexia.
- Warn that stopping the medication may lead to rebound bingeing and renewed body‑image distress.
- Advocate for structured meal plans, regular eating, and emotional regulation work, even if a client continues GLP‑1s.

The “Easy Fix” Is Not the Fix
GLP‑1s are not inherently evil and they are not inherently good. They are a tool, and tools can be used for “good” or for “harm.” I see them as an amplifier of what is already there in the threads of our society: the longing for thinness, the problematic, harmful history of fat phobia, and the wish for a quick escape from shame.

Our job at clinicians is not to decide for our patients whether to use GLP‑1s, but to ensure they understand the full picture, including the short‑term benefits, the long‑term unknowns, and the psychological trade‑offs. We must be ready to sit with the discomfort of “what if this helps?” and “what if this breaks them?” And remember that evidence-based eating disorder therapy can offer something GLP‑1s cannot: a way to live with a body that feels real, human, and worthy, even when it is not smaller. The “easy fix” is seductive. Recovery is not. And that is why we must hold both truths at once.